Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.
In patients with HoFH, lomitapide led to a significant reduction of LDL-c levels and to achievement of EAS targets in many patients, while CV event rates correlated with LDL-c levels.
A subanalysis of the ORION-1 phase II trial showed that inclisiran reduced LDL-c in high CV risk patients, irrespective of presence of diabetes.
This review describes six mechanisms underlying HFpEF with potential translational significance; three haemodynamic mechanisms and cellular/molecular mechanisms.
In two trials of the EASE phase III program, the primary endpoint of change in HbA1c after 26 week of empagliflozin in addition to insulin was met in type 1 diabetes patients.
Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.
ADA 2018 In the OBSERVE-4D real world study, canagliflozin did not result in increased risk of below-knee amputation in T2DM patients or patients with established CVD.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels
In type 2 diabetes patients, semaglutide showed greater reductions of HbA1c and weight compared with liraglutide in the PIONEER 4 trial and compared with sitagliptin in the PIONEER 7 trial.
ADA 2018 In the long-term Danish Steno 2 study, interventions targeting complications were found to improve disease-free-life length, and costs were not higher than with conventional treatment.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.